Skip to main content

Table 1 Whole genome bisulfite sequencing of 13 human samples

From: Epigenomic analysis detects aberrant super-enhancer DNA methylation in human cancer

Sample ID Status Tissue Origin Total reads Coverage genome Coverage CpG Average methylation SEa SE coveredb
CD19 Normal B cells Primary 318714023 6.0 14.1 76.0 688 99.0 %
Brain Normal Brain (white matter) Primary 557237398 11.1 7.0 77.1 1067 99.6 %
Breast Normal Breast Primary 606872747 15.1 32.1 73.0 1099 99.5 %
Colon Normal Colon Primary 609043678 13.7 24.3 69.6 1023 99.4 %
Lung Normal Lung Primary 333333332 7.2 8.7 74.4 1286 99.1 %
Colon_P Cancer Colorectal cancer Primary 670281443 16.7 24.6 66.5 1023 99.4 %
Colon_M Cancer Colorectal cancer metastasis Primary 652566967 16.3 24.7 62.4 1023 99.4 %
MDA-MB-468PT Cancer Breast cancer Cell line 626288553 15.4 37.6 57.1 1099 99.4 %
MDA-MB-468LN Cancer Breast cancer metastasis Cell line 600134926 14.3 37.1 42.8 1099 99.5 %
U87MG Cancer Glioblastoma Cell line 281524883 6.3 8.5 55.7 1067 99.6 %
H1437 Cancer Lung adenocarcinoma Cell line 333333332 7.9 10.3 48.1 1286 99.1 %
H1672 Cancer Small cell lung cancer Cell line 329691560 7.4 10.5 65.6 1286 99.1 %
H157 Cancer Lung squamous cell cancer Cell line 333333332 7.8 10.7 41.8 1286 99.2 %
  1. a SE is the number of super-enhancer regions determined in the respective normal tissue samples [11]
  2. bSE covered is the percentage of super-enhancers covered by WGBS (>50 % of CpG sites)